NeoMatrix Therapeutics, Inc., a clinical-stage company focused on developing a portfolio of novel, bioactive peptides with important potential for the treatment of burns and other types of tissue injury, today announced positive topline data from its Phase 1 clinical trial of NMT-cP12, its lead candidate for the treatment of severe burns.
September 24, 2020
· 6 min read